These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 17083507)

  • 21. Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A.
    Klintman J; Hillarp A; Donfield S; Berntorp E; Astermark J
    Haemophilia; 2013 Jan; 19(1):106-12. PubMed ID: 22762454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII.
    Gringeri A; Tagliaferri A; Tagariello G; Morfini M; Santagostino E; Mannucci P;
    Br J Haematol; 2004 Aug; 126(3):398-404. PubMed ID: 15257713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A.
    Fukui H; Yoshioka A; Shima M; Tanaka I; Koshihara K; Fukutake K; Fujimaki M
    Int J Hematol; 1991 Oct; 54(5):419-27. PubMed ID: 1756252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate): a prospective pharmacovigilance study.
    Ewenstein BM; Gomperts ED; Pearson S; O'Banion ME
    Haemophilia; 2004 Sep; 10(5):491-8. PubMed ID: 15357776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: descriptive meta-analysis of post-marketing study data.
    Yoshioka A; Fukutake K; Takamatsu J; Shirahata A;
    Int J Hematol; 2006 Aug; 84(2):158-65. PubMed ID: 16926139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel therapies for immune tolerance in haemophilia A.
    Collins PW
    Haemophilia; 2006 Dec; 12 Suppl 6():94-100; discussion 100-1. PubMed ID: 17123401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Previously untreated patients and recombinant factor VIII concentrate studies.
    Pasi KJ
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S29-32. PubMed ID: 9351534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview of inhibitors.
    Astermark J
    Semin Hematol; 2006 Apr; 43(2 Suppl 4):S3-7. PubMed ID: 16690373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of cytokine genes polymorphism as markers for inhibitor development in haemophilia A.
    Chaves D; Belisário A; Castro G; Santoro M; Rodrigues C
    Int J Immunogenet; 2010 Apr; 37(2):79-82. PubMed ID: 20082647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics of inhibitors in mild/moderate haemophilia A.
    Peerlinck K; Jacquemin M
    Haemophilia; 2006 Dec; 12 Suppl 6():43-7. PubMed ID: 17123393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products.
    Rota M; Cortesi PA; Steinitz-Trost KN; Reininger AJ; Gringeri A; Mantovani LG
    Blood Coagul Fibrinolysis; 2017 Dec; 28(8):627-637. PubMed ID: 28678027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
    Delignat S; Dasgupta S; André S; Navarrete AM; Kaveri SV; Bayry J; André MH; Chtourou S; Tellier Z; Lacroix-Desmazes S
    Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transient factor VIII inhibitor in a hemophilia patient after staphylococcal septic shock syndrome.
    Yamamoto K; Niiya K; Shigematu T; Kiguchi T; Takenaka K; Shinagawa K; Ishimaru F; Ikeda K; Shima M; Harada M
    Int J Hematol; 2000 Dec; 72(4):517-9. PubMed ID: 11197224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development.
    Ettingshausen CE; Kreuz W
    Haemophilia; 2006 Dec; 12 Suppl 6():102-6. PubMed ID: 17123402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
    Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.
    Gringeri A; Musso R; Mazzucconi MG; Piseddu G; Schiavoni M; Pignoloni P; Mannucci PM;
    Haemophilia; 2007 Jul; 13(4):373-9. PubMed ID: 17610550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant factor VIII concentrates.
    Franchini M; Lippi G
    Semin Thromb Hemost; 2010 Jul; 36(5):493-7. PubMed ID: 20632247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies.
    Aledort LM; Navickis RJ; Wilkes MM
    J Thromb Haemost; 2011 Nov; 9(11):2180-92. PubMed ID: 21848690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
    Tagariello G; Zanotto D; Radossi P; Sartori R; Belvini D; Salviato R
    Am J Hematol; 2007 Jun; 82(6):460-2. PubMed ID: 17211843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.